Misyo (Methadone Hydrochloride)

Methadone, the active ingredient in Misyo, is an opioid agonist presented as an oral dosage form for oral use. It is employed in the management of opioid dependence and chronic pain in adult patients who require long‑term opioid therapy.

GNH USA supplies Misyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone acts on the opioid system and is indicated for conditions that require opioid substitution or analgesia.

Opioid dependence treatment: reduces withdrawal symptoms and cravings during maintenance therapy. Chronic pain management: provides long‑acting analgesia for severe, persistent pain. Opioid substitution therapy: facilitates transition from illicit opioids to a regulated regimen.

Methadone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Nausea or vomiting: gastrointestinal upset. - Drowsiness or sedation: central nervous system depression. - Sweating: autonomic activation. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: life‑threatening breathing slowdown. - Cardiac arrhythmias (QT prolongation): risk of torsades de pointes. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

Methadone requires careful monitoring due to its potency and pharmacokinetic profile.

Dose titration: adjust gradually under medical supervision to avoid overdose. Respiratory monitoring: watch for signs of depression, especially during initiation. Cardiac assessment: obtain baseline ECG and monitor QT interval. Drug dependence: assess for potential misuse or diversion. Pregnancy and lactation: evaluate risk‑benefit before use. Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture and light.

Methadone interacts with several drug classes that can alter its safety or efficacy.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase methadone levels, risk of toxicity. - QT‑prolonging agents (e.g., quinidine, haloperidol): additive risk of arrhythmia. - CNS depressants (e.g., benzodiazepines, barbiturates): potentiate respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2B6 inducers (e.g., rifampin, carbamazepine): may lower methadone concentrations. - Antidepressants (e.g., SSRIs, SNRIs): can affect serotonin pathways. - Herbal supplements (e.g., St. John’s wort): may alter metabolism.